Characterization of poliovirus neutralization escape mutants of single-domain antibody fragments (VHHs)

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4695-4706

  Schotte, Lise ^a   Thys, Bert ^a   Strauss, Mike ^b   Filman, David J ^b   Rombaut, Bart ^a   Hogle, James M ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIRODAVIR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ANTIVIRUS AGENT; CAPSID PROTEIN; IMMUNOGLOBULIN FRAGMENT; NEUTRALIZING ANTIBODY; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN POLIOVIRUS 1; IN VITRO STUDY; NONHUMAN; POLIOVIRUS NEUTRALIZATION ESCAPE MUTANT; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS MUTANT; VIRUS NEUTRALIZATION; DRUG EFFECTS; IMMUNOLOGY; MUTATION; POLIOMYELITIS VIRUS; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; BINDING SITES; CAPSID PROTEINS; CELL LINE, TUMOR; HELA CELLS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MUTATION; POLIOVIRUS; VIRAL PROTEINS;

EID: 84940214008     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00878-15     Document Type: Article

References (40)

1. Salk JE. 1955. Vaccination against paralytic poliomyelitis performance and prospects. Am J Public Health Nations Health 45:575-596. http://dx.doi.org/10.2105/AJPH.45.5-Pt-1.575.
2. Sabin AB. 1955. Immunization of chimpanzees and human beings with avirulent strains of poliomyelitis virus. Ann N Y Acad Sci 61:1050-1056. http://dx.doi.org/10.1111/j.1749-6632.1955.tb42565.x.
3. Hara M, Saito Y, Komatsu T, Kodama H, Abo W, Chiba S, Nakao T. 1981. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol 25:905-913. http://dx.doi.org/10.1111/j.1348-0421.1981.tb00095.x.
4. Committee on Development of a Polio Antiviral and its Potential Role in Global Poliomyelitis Eradication NRC. 2006. Exploring the role of antiviral drugs in the eradication of polio: workshop report. The National Academies Press, Washington, DC.
5. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, van der Werf S, Anderson CW, Wimmer E. 1981. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291:547-553. http://dx.doi.org/10.1038/291547a0.
6. Baltimore D, Eggers HJ, Franklin RM, Tamm I. 1963. Poliovirus-induced RNA polymerase and the effects of virus-specific inhibitors on its production. Proc Natl Acad SciUSA49:843-849. http://dx.doi.org/10.1073/pnas.49.6.843.
7. Jarvis TC, Kirkegaard K. 1992. Poliovirus RNA recombination: mechanistic studies in the absence of selection. EMBO J 11:3135-3145.
8. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA98:6895-6900. http://dx.doi.org/10.1073/pnas.111085598.
9. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. 1986. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 59:377-383.
10. Wang W, Lee WM, Mosser AG, Rueckert RR. 1998. WIN 52035- dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface. J Virol 72:1210-1218.
11. Koch F, Koch G. 1985. The molecular biology of poliovirus. Springer-Verlag, Vienna, Austria.
12. Mosser AG, Rueckert RR. 1993. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J Virol 67:1246-1254.
13. Thys B, Schotte L, Muyldermans S, Wernery U, Hassanzadeh- Ghassabeh G, Rombaut B. 2010. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antiviral Res 87:257-264. http://dx.doi.org/10.1016/j.antiviral.2010.05.012.
14. Muyldermans S. 2001. Single domain camel antibodies: current status. J Biotechnol 74:277-302.
15. Arbabi GM, Desmyter A, Wyns L, Hamers R, Muyldermans S. 1997. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414:521-526. http://dx.doi.org/10.1016/S0014-5793(97)01062-4.
16. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. 1993. Naturally occurring antibodies devoid of light chains. Nature 363:446-448. http://dx.doi.org/10.1038/363446a0.
17. Frenken LG, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B, Verrips CT. 2000. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 78:11-21. http://dx.doi.org/10.1016/S0168-1656(99)00228-X.
18. Schotte L, Strauss M, Thys B, Halewyck H, Filman DJ, Bostina M, Hogle JM, Rombaut B. 2014. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity. J Virol 88: 4403-4413. http://dx.doi.org/10.1128/JVI.03402-13.
19. Belnap DM, McDermott BM, Jr, Filman DJ, Cheng N, Trus BL, Zuccola HJ, Racaniello VR, Hogle JM, Steven AC. 2000. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci USA97:73-78. http://dx.doi.org/10.1073/pnas.97.1.73.
20. Colston E, Racaniello VR. 1994. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J 13:5855-5862.
21. He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ, Rossmann MG. 2000. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci U S A97:79-84. http://dx.doi.org/10.1073/pnas.97.1.79.
22. Strauss M, Filman DJ, Belnap DM, Cheng N, Noel RT, Hogle JM. 2015. Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry. J Virol 89:4143-4157. http://dx.doi.org/10.1128/JVI.03101-14.
23. Zhang P, Mueller S, Morais MC, Bator CM, Bowman VD, Hafenstein S, Wimmer E, Rossmann MG. 2008. Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses. Proc Natl Acad Sci USA105:18284-18289. http://dx.doi.org/10.1073/pnas.0807848105.
24. Everaert L, Vrijsen R, Boeye A. 1989. Eclipse products of poliovirus after cold-synchronized infection of HeLa cells. Virology 171:76-82. http://dx.doi.org/10.1016/0042-6822(89)90512-6.
25. Brioen P, Sijens RJ, Vrijsen R, Rombaut B, Thomas AA, Jackers A, Boeye A. 1982. Hybridoma antibodies to poliovirus N and H antigen. Arch Virol 74:325-330. http://dx.doi.org/10.1007/BF01314165.
26. Hogle JM, Chow M, Filman DJ. 1985. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229:1358-1365. http://dx.doi.org/10.1126/science.2994218.
27. Emini EA, Jameson BA, Lewis AJ, Larsen GR, Wimmer E. 1982. Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies. J Virol 43:997-1005.
28. Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Horodniceanu F. 1983. Natural variation of poliovirus neutralization epitopes. Infect Immun 41:1217-1225.
29. Minor PD, Schild GC, Bootman J, Evans DM, Ferguson M, Reeve P, Spitz M, Stanway G, Cann AJ, Hauptmann R, Clarke LD, Mountford RC, Almond JW. 1983. Location and primary structure of a major antigenic site for poliovirus neutralization. Nature 301:674-679. http://dx.doi.org/10.1038/301674a0.
30. Minor PD, Evans DM, Ferguson M, Schild GC, Westrop G, Almond JW. 1985. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. J Gen Virol 66(Part 5):1159-1165. http://dx.doi.org/10.1099/0022-1317-66-5-1159.
31. Ferguson M, Evans DM, Magrath DI, Minor PD, Almond JW, Schild GC. 1985. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3. Virology 143:505-515. http://dx.doi.org/10.1016/0042-6822(85)90389-7.
32. Diamond DC, Jameson BA, Bonin J, Kohara M, Abe S, Itoh H, Komatsu T, Arita M, Kuge S, Nomoto A, Osterhaus ADME, Crainic R, Wimmer E. 1985. Antigenic variation and resistance to neutralization in poliovirus type 1. Science 229:1090-1093. http://dx.doi.org/10.1126/science.2412292.
33. Hogle JM, Filman DJ. 1989. The antigenic structure of poliovirus. Philos Trans R Soc Lond B Biol Sci 323:467-478. http://dx.doi.org/10.1098/rstb.1989.0024.
34. Fiore L, Ridolfi B, Genovese D, Buttinelli G, Lucioli S, Lahm A, Ruggeri FM. 1997. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. J Virol 71:6905-6912.
35. Drexler JF, Grard G, Lukashev AN, Kozlovskaya LI, Bottcher S, Uslu G, Reimerink J, Gmyl AP, Taty-Taty R, Lekana-Douki SE, Nkoghe D, Eis-Hubinger AM, Diedrich S, Koopmans M, Leroy EM, Drosten C. 2014. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc Natl Acad Sci U S A 111:12889-12894. http://dx.doi.org/10.1073/pnas.1323502111.
36. Blondel B, Crainic R, Fichot O, Dufraisse G, Candrea A, Diamond D, Girard M, Horaud F. 1986. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J Virol 57:81-90.
37. Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R. 2011. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol 85:4354-4362. http://dx.doi.org/10.1128/JVI.02553-10.
38. Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, Makiya M, Agulto L, Purcell RH, Chumakov K. 2013. Crossneutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A 110:20242-20247. http://dx.doi.org/10.1073/pnas.1320041110.
39. Liu HM, Roberts JA, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS, Oberste MS. 2012. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob Agents Chemother 56:5568-5574. http://dx.doi.org/10.1128/AAC.00539-12.
40. Genovese D, Catone S, Farah ME, Gambacorta A, Fiore L. 1999. Isolation and biological characterization of 3(2H)-isoflavene-resistant and -dependent poliovirus type 2 Sabin mutants. J Gen Virol 80(Part 1):157-167.